Biogen Idec and Elan Corporation, plc have announced new data on the global utilization, safety and overall patient exposure of TYSABRI® ((natalizumab); humanized by MRCT). “These data suggest that neurologists and patients are increasingly choosing TYSABRI for the treatment of their disease.” Click here to read the full article on PharmaLive.
New Tysabri data released
News releases
Related news
TYSABRI gains market approval
New UK-based research project brings together world-leading institutions to transform care for people living with dementia
